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Editorial
Endovascular therapy for peripheral arterial disease in the femoropopliteal 
territory: an evolving promising scenario
Terapia endovascular para a doença arterial periférica no território fêmoro-poplíteo: um cenário 
promissor em evolução
Peripheral arterial disease (PAD) affects 8 to 10 million people in 
United States. Statistics regarding its prevalence in Brazil are scarce, 
varying from 3%, between 40 to 59 years, up to 20% in patients above 
70 years old,1 with an increasing trend as a result of higher life ex-
pectancy among the general population, as well as due to the con-
temporary pandemic context of some chronic diseases, mainly in 
Western societies, namely diabetes, obesity, and dyslipidemia.2-4 It 
has a major harmful impact on quality of life and is an under-recog-
nized marker of multisystem vascular disease. The risk of disease 
increases two to three-fold for every 10-year increase in age after 40 
years, with men developing claudication about twice as commonly 
as women.2,3 Mortality in patients with intermittent claudication is 
up to four times that of non-claudicants.3,4
Atherosclerotic lesions in lower limbs present relative symmetry 
(# 80%), despite the variable severity among such lesions. Concomi-
tant adjacent lesions are very common, with iliac lesions occurring 
in 46% and below-the-knee lesions in up to 38% of patients.4
The initial conventional concept of non-surgical revasculariza-
tion was introduced by Charles Dotter and Grüentzig. Since then, 
endovascular science has progressed impressively, especially during 
the past decade, when dramatic changes have occurred in the surgi-
cal management of patients with chronic critical limb ischemia, as 
well as in the way we define clinical success after revascularization. 
Endovascular interventions for treatment of critical limb ischemia 
and PAD have increased prolifically, with almost 40% performed in 
the femoropopliteal segment, and they are now performed more 
commonly than lower extremity bypass in many specialized vascu-
lar centers. Amputation rates have concomitantly declined 25% du-
ring this time.4,5
Stenotic femoropopliteal segment lesions are commonly short 
(# 80% < 5 cm). Nevertheless, occlusions are rarely shorter than 5 cm 
(# 9%).4 Long segment recanalization of chronic total occlusions can 
be a valuable treatment option for patients with severe critical limb 
ischemia or intermittent claudication. It has been used since the 
1990s to prolong the need for bypass in critical limb ischemia, and to 
provide pain relief in severe, lifestyle-limiting claudication from 
chronic vessel occlusion. Several techniques and devices have been 
identified as safe and practical in the approach to vascular recanali-
zation. Originally used in the femoropopliteal segment, its role has 
been extended to the treatment of aortoiliac and infrapopliteal le-
sions, including the recanalization of trifurcation and long tibial oc-
clusions. Technical success, primary patency, and complication rates 
appear not to be significantly different whether performed intralu-
minally or subintimally.5 
Chronic total occlusions of the femoropopliteal and trifurcation 
vessels are classified as TASC II types C and D lesions, and surgical 
revascularization is traditionally the treatment of choice.2 The ad-
vent of new endovascular techniques and devices has changed the 
landscape of vascular intervention, allowing these lesions to be tre-
ated by endovascular means.
The discussion surrounding endovascular interventions in 
PAD, particularly in the femoropopliteal segment, has gained 
outstanding relevance, especially in the last decade, due to a re-
latively disappointing (nevertheless evolving) long-term effica-
cy outcomes among available solutions in this segment, mainly 
after plain balloon angioplasty and/or atherectomy, whether 
utilizing balloons or stents, has also widened the therapeutic 
scenario, as well as the so-called third-generation auto-expan-
dable nitinol stents.
Stenting in this segment has been challenging, frequently im-
planted on a bail-out basis and mainly performed after significant 
recoil, insufficient angioplasty, or flow-limiting dissection. The stent 
deployment rate increases directly with length. This arterial seg-
ment is submitted to several different forces, which negatively in-
fluence stent, clinical, and angiographic performances. Particularly 
in the femoropopliteal transition, the artery is subjected to com-
pression, flexion, bending, and rotation forces during regular move-
ment. Patency and target lesion revascularization rates have been 
disappointing, mainly due to a considerable stent fracture rate.6 
Fractures are related not only with the type of stent, being much 
more frequent in balloon- and next-generation auto-expansive niti-
nol stents, but also with the number and length of such devices de-
ployed, leading to earlier restenosis and occlusion.6 Several 
next-generation auto-expansive nitinol stent devices have shown 
promising results, with very low fracture rates that have enhanced 
their patency.7-10 
The so-called third-generation auto-expandable nitinol stents re-
present a clear improvement in terms of size, profile, navigability, and 
delivery system. Design has been also of significant importance, with 
biomimetic features enhancing performance by improved resistance 
to crushing force and flexibility, as well as reduced chronic outward 
force, which has resulted in better fracture ratios since then.8 
Regardless of the unquestionable progress of new generation re-
garding stent fractures, primary stenting in short femoropopliteal 
lesions appears not to be cost-effective. 
This edition of Revista Brasileira de Cardiologia Invasiva presents a 
very interesting retrospective single center study, evaluating the safe-
ty and efficacy of two third-generation self-expandable nitinol stents 
within a short-term follow-up period. Despite a small sample size, the 
researchers could evaluate their early performance in a very challen-
ging scenario, with a majority of diabetic patients having highly ad-
vanced disease, poor below-the-knee runoff, and long lesion length. 
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Nevertheless, most procedures could be performed with only one 
stent, resulting in promising primary patency and limb salvage rates, 
as well as an absence of stent fractures in this period.
The advances achieved from these novel stent devices represent 
an improvement in this unfavorable scenario, namely in long and 
calcified chronic total occlusions in the femoropopliteal region. Fur-
ther prospective randomized studies regarding this issue, including 
comparisons of different available technical solutions and their out-
comes, are warranted.
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